TY - JOUR
T1 - A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m 2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors
AU - Isohashi, Fumiaki
AU - Takano, Tadao
AU - Onuki, Mamiko
AU - Arimoto, Takahide
AU - Kawamura, Naoki
AU - Hara, Ryusuke
AU - Kawano, Yoshiaki
AU - Ota, Yukinobu
AU - Inokuchi, Haruo
AU - Shinjo, Hidenori
AU - Saito, Toshiaki
AU - Fujiwara, Satoe
AU - Sawasaki, Takashi
AU - Ando, Ken
AU - Horie, Koji
AU - Okamoto, Hiroyuki
AU - Murakami, Naoya
AU - Hasumi, Yoko
AU - Kasamatsu, Takahiro
AU - Toita, Takafumi
N1 - Funding Information:
Acknowledgements This study was supported in part by the National Cancer Center Research and Development Fund (26-A-4).
Publisher Copyright:
© 2018, The Author(s).
PY - 2019/5/15
Y1 - 2019/5/15
N2 - Background: The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m 2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors. Methods: We conducted a retrospective multi-institutional chart review of postoperative uterine cervical cancer patients with high-risk prognostic factors who had been treated with both 3DRT and weekly 40-mg/m 2 cisplatin from 2007 to 2012. Each participating hospital provided detailed information regarding patient characteristics, treatment outcomes, and treatment complications. Results: The eligible 96 patients were analyzed. The median follow-up period was 61 months. The 3-year relapse-free survival, overall survival (OS), and locoregional relapse-free survival (LRFS) rates were 76%, 90%, and 88%, respectively. In multivariate analysis, the histological finding of either adenocarcinoma or adenosquamous carcinoma was a significant risk factor for both OS and LRFS. The percentage of patients with grade ≥ 3 acute hematologic toxicity, acute lower gastrointestinal toxicity (GIT), and late lower GIT were 45%, 19%, and 17%, respectively. Conclusions: The outcomes of concurrent chemoradiotherapy (CCRT) using weekly 40-mg/m 2 cisplatin are similar to those in the previous studies that used several chemotherapy regimens. However, postoperative CCRT using 3DRT had a high level of late GIT.
AB - Background: The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m 2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors. Methods: We conducted a retrospective multi-institutional chart review of postoperative uterine cervical cancer patients with high-risk prognostic factors who had been treated with both 3DRT and weekly 40-mg/m 2 cisplatin from 2007 to 2012. Each participating hospital provided detailed information regarding patient characteristics, treatment outcomes, and treatment complications. Results: The eligible 96 patients were analyzed. The median follow-up period was 61 months. The 3-year relapse-free survival, overall survival (OS), and locoregional relapse-free survival (LRFS) rates were 76%, 90%, and 88%, respectively. In multivariate analysis, the histological finding of either adenocarcinoma or adenosquamous carcinoma was a significant risk factor for both OS and LRFS. The percentage of patients with grade ≥ 3 acute hematologic toxicity, acute lower gastrointestinal toxicity (GIT), and late lower GIT were 45%, 19%, and 17%, respectively. Conclusions: The outcomes of concurrent chemoradiotherapy (CCRT) using weekly 40-mg/m 2 cisplatin are similar to those in the previous studies that used several chemotherapy regimens. However, postoperative CCRT using 3DRT had a high level of late GIT.
KW - Cervical cancer
KW - Cisplatin
KW - Concurrent chemoradiotherapy
KW - Postoperative
KW - Three-dimensional radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85058964259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058964259&partnerID=8YFLogxK
U2 - 10.1007/s10147-018-01380-z
DO - 10.1007/s10147-018-01380-z
M3 - Article
C2 - 30580379
AN - SCOPUS:85058964259
VL - 24
SP - 575
EP - 582
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
SN - 1341-9625
IS - 5
ER -
